OM:ONCOBiotechs
Oncopeptides (OM:ONCO): Losses Narrow 43% Annually, Growth Outlook Sharpens Valuation Debate
Oncopeptides (OM:ONCO) remains unprofitable, but has aggressively narrowed its losses by 43.3% per year over the past five years. With earnings expected to surge by 95.25% each year and profitability projected within the next three years, investors have plenty to weigh against near-term risks as the company targets annual revenue growth of 71.2%, far outpacing the wider Swedish market.
See our full analysis for Oncopeptides.
The next step is to see how these figures compare with the broader...